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Abstract   
 
Background: Migraine headache is a debilitating disorder that is difficult to manage and is often 
treated in the emergency department (ED). Many standard abortive therapies used in the ED 
have mixed efficacy and lead to unsatisfactory results. Propofol is a proposed treatment for acute 
migraine with the potential to have better efficacy than standard ED abortive medications. This 
review evaluates propofol’s effectiveness at reducing pain severity and headache recurrence in 
adult patients with migraine headache when compared to typical abortive therapies. 
 
Methods:  An exhaustive search of medical literature was completed using Medline-OVID, 
CINAHL, EBMR Multifile, and Web of Science. Key words used included: propofol, migraine, 
and headache. Relevant articles were assessed for quality using GRADE.  
 
Results:  Twenty-two articles were reviewed for relevancy. Two randomized, double blind 
studies met inclusion criteria and were included in this systematic review. The first randomized, 
double blind trial was conducted in an ED and demonstrated a significant decrease in pain 
severity, nausea and vomiting, and headache relapse within 24 hours when compared to 
sumatriptan. The second randomized, double blind trial was conducted in an ED and 
demonstrated a significant decrease in pain severity when compared to dexamethasone. Both 
studies revealed a significantly faster rate of pain severity reduction when compared to 
sumatriptan and dexamethasone. 
 
Conclusion:  Propofol can be an ideal abortive therapy for acute migraine in the ED. It has been 
shown to be more effective than sumatriptan and dexamethasone at treating migraine headache. 
More research is needed to compare propofol’s efficacy to these and other accepted abortive 
therapies.  
 
Keywords: Propofol, migraine, headache, emergency department 
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Propofol for the Abortive Treatment of Adult Migraine Headache in the Emergency 
Department 
BACKGROUND 
 Migraine headaches are a common neurological disorder that can result in debilitating 
symptoms. It affects 18% of females and 7% of males in the United States with the highest 
prevalence between the ages of 35-45 years.1 The majority of migraine sufferers report 
functional and cognitive impairment due to their headaches and on average lose 20 days of work 
and productivity each year.2,3 Migraine headaches have become the 19th most disabling disorder 
worldwide according to the World Health Organization (WHO).4 Many persons with migraine 
will visit the emergency department (ED) for relief of their symptoms not abated by standard 
outpatient therapies. Migraine cases represent 2.2% of all ED visits.5 Current recommended ED 
abortive therapies include medications in the triptan class, antiemetics such as prochlorperazine 
and metoclopramide, dexamethasone, and more.6 Unfortunately, these current treatments have 
unwanted side effects, mixed efficacy, and up to 49% recurrence rate7 after treatment which is 
problematic for already congested EDs and for patients who have sought out effective treatment.  
 Current abortive treatments are not always effective for migraine sufferers because the 
mechanism of a migraine headache is not fully understood. Research has proven that multiple 
components including the central and peripheral nervous systems, the trigeminovascular system, 
the cerebral cortex, and vasculature of the meningeal and extra-cranial arteries all play a role in 
the initiation and continuation of a migraine.8  This evidence compels researchers to continue to 
search for more effective treatments for those patients who do not adequately respond to current 
abortive therapies.  
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 Triptans are a family of tryptamine based medications that function by targeting and 
agonizing 5HT 1b/1d receptors which inhibit release of vasoactive neuropeptides, inhibit pain 
pathways within the trigeminocervical complex, and decrease nociceptive neurotransmission.9,10 
Clinical success rate has been reported between 70-80%.11 A comparative effectiveness review 
(CER)12 found triptans to have a mean difference of pain intensity reduction versus placebo on a 
visual analog scale (VAS) of 15%. Triptan use in the ED is limited. It is estimated that 25% of 
patients will be non-responders and that up to 40% will have recurrence of their headache within 
24 hours.13 Triptans also have unwanted side effects such as nausea and vomiting, paresthesias, 
and injection site reactions. Treatment with this drug classis also contraindicated in persons with 
cardiovascular disease, ischemic stroke, and pregnancy.6 
 Prochlorperazine and metoclopramide are useful in migraine headaches because of their 
antiemetic properties. They decrease nausea and vomiting by antagonizing dopamine receptors 
and inhibiting stimulation of chemoreceptor triggerzones.11 Prochlorperazine and 
metoclopramide have also been found to reduce pain perception through their neuroleptic actions 
and central dopamine agonistic effects respectively.11,14 Prochlorperazine and metoclopramide 
have shown a clinical success rate of 67%-92% and 67% respectively.11 The CER12 found 
prochlorperazine and metoclopramide to have a mean difference of pain intensity reduction 
versus placebo on a VAS of 47% and 22% respectively. They also found that there was no 
significant difference in headache relapse when compared to placebo.12 These antiemetics have 
been proven to be useful in the ED but they also have unwanted side effects including sedation, 
postural hypotension, dystonia, and akathisia.6,11 It is highly recommended that diphenhydramine 
be administered simultaneously with both antiemetics to reduce possibility of akathisia.6   
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 Dexamethasone is a corticosteroid thought to be effective for migraine headache by its 
anti-inflammatory effects.15 It is believed to decrease perivascular neurogenic inflammation and 
central and peripheral sensitization.15 Oral steroids are commonly prescribed when the use of 
other abortive therapies have failed but studies suggest little benefit in initial pain reduction.15,16 
Although, dexamethasone has proven beneficial in stopping recurrence of headache within 24-72 
hours after initial treatment and should be administered before discharge from the ED.16 
Dexamethasone has few serious side effects when administered in a one-time bolus form. These 
include hyperglycemia, mood disturbance, and insomnia.15 Patients were also found to be more 
likely to experience dizziness when compared to placebo.12  
 A new proposed abortive treatment for acute migraine is the anesthetic agent, propofol. 
Propofol’s mechanism of action is through its agonist activity at gamma aminobutyric acid A 
(GABAA) beta 1 subunits, leading to hyperpolarization and inhibition of neuronal firing.17 It also 
has shown to enhance anti-nociceptive dorsal root potential by mediating depolarization of 
primary afferent nerve terminals and vasodilates vascular smooth muscle by modifying calcium 
dependent pathways.18,19  
 Krusz et al17 published the first study of propofol use for migraine headache in 2000. The 
authors hypothesized that the GABAergic system may be in a low functional state during an 
intractable headache and that it may be overcome by stimulating the GABAA  receptors.17  This 
study found that propofol, on average, reduced migraine headache pain severity on a VAS by 
95.4%.17 All cases of nausea and vomiting were completely resolved and only 4% of patients had 
headache relapse within 24 hours.17 No significant adverse events except for transiently slurred 
speech or drowsiness were reported.17 Additional case studies20-23 have also proven propofol to 
be safe and effective at treating migraine headaches. Can propofol be more effective at reducing 
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pain intensity and headache relapse in adult patients with migraine headache when compared to 
current recommended abortive therapies in the emergency department? 
METHODS 
 An exhaustive search of medical literature was completed using Medline-OVID, 
CINAHL, EBMR Multifile, and Web of Science using the key words: propofol, migraine, and 
headache. These sources were then narrowed to only include articles which evaluated the 
treatment of migraine headache with propofol in adult patients. The bibliographies of these 
articles were further evaluated for relevant sources. Applicable articles were assessed for quality 
using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)24  
RESULTS 
 The initial search yielded 22 articles for review. After screening the articles for relevant 
data two articles met inclusion criteria. Both of these articles were randomized controlled 
trials25,26 and can be seen in Table I. 
Moshtaghion et al 
 This randomized, double blind study26 investigated the effectiveness of propofol versus 
sumatriptan in treating acute migraine headache pain intensity, nausea and vomiting, and the 
resulting adverse side effects. Minimum necessary calculated sample size was 45 participants in 
each group. There were 91 patients, between the ages of 18-45, who presented to the emergency 
department, met the International Headache Society (IHS) criteria for migraine, and were 
enrolled in this study. Exclusion criteria included pregnancy, coronary or vascular disease, 
allergy to the medication or its components, opium dependence, diastolic blood pressure > 
105mm Hg, and the use of ergotamine or 5HT agonists within the past 24 hours.26  
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 Participants were randomly allocated into either Group 1: sumatriptan, or Group 2: 
propofol, using a random number table. The two treatment groups were prognostically balanced 
in demographic and baseline characteristics. The patients were assessed by an ED physician for 
headache severity using an 11-point VAS, as well for symptoms including nausea, vomiting, 
photophobia, and phonophobia before receiving treatment. The ED physicians were blinded to 
the patients’ assigned groups. All patients had an intravenous (IV) line established and were 
given a 500ml infusion of normal saline (NS). All syringes were wrapped so that the contents 
were indistinguishable by patients. All syringe contents were administered by an anesthesiology 
resident.  Group 1 received 6mg of sumatriptan injected subcutaneously with an accompanying 
3.5mL IV infusion of NS. An additional 1.5mL bolus of NS was administered every 4 minutes 
following the initial infusion up to a final dose of 7.5mL. Group 2 received 0.5mL of NS injected 
subcutaneously with an accompanying 30-40mg IV infusion of propofol. An additional 10-20mg 
bolus of propofol was administered every 3-5 minutes following the initial infusion up to a 
maximum dose of 120mg. Patients in group 2 were sedated to a Ramsey score of 3 to 4. If 
patients had persistent nausea or vomiting after treatment with either therapy, they were given a 
1mg infusion of IV granisetron.26  
 Each patient was reassessed for headache severity, improvement in accompanying 
symptoms, and adverse effects at 30 minutes, 60 minutes and 2 hours post treatment by the 
original ED physician who assessed them upon admission. Of the 91 patients enrolled in this 
study, one patient, in Group 1, could not complete the study due to severe chest tightness after 
administration of therapy. The remaining 90 patients were reassessed by phone call 24 hours 
later for headache recurrence.26 
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 Pain intensity in the propofol group was significantly lower at 30 minutes when 
compared to the sumatriptan group (P= 0.034). As well, the rate of pain intensity reduction in the 
propofol group was significantly faster (P= 0.002).) However, pain intensity at 1 and 2 hours 
post therapy and response to therapy was similar in both groups (P= 0.53, 0.53, 0.78 
respectively). Need for antiemetic therapy and the rate of headache recurrence was significantly 
lower in the propofol group (P= 0.045, 0.001). However, symptom improvement of photophobia 
and phonophobia at the time of discharge was not significantly different when compared to the 
sumatriptan group (P= 0.65, 0.29). Adverse effects including chest tightness and rash at injection 
site were also significantly lower in the propofol group (P= 0.001). No significant difference in 
hypotension and drowsiness was found when comparing the two groups.26 See Table II. 
 The main limitation mentioned in this study was the lack of a standard questionnaire used 
when assessing the patient for recurrence of their headache within 24 hours. In this study follow 
up was conducted by calling the patient and simply inquiring for headache recurrence.26  
Soleimanpour et al 
 This randomized, double blind clinical trial25 investigated the effectiveness of propofol 
versus dexamethasone in treating migraine headache pain intensity. Again, calculated sample 
size was 45 patients for each group. There were 90 patients, aged ≥ 18 years, who presented to 
the emergency department, met the IHS criteria for migraine, and were enrolled in this study. 
Exclusion criteria included a history of receiving prior abortive medications before presentation 
to the ED, allergy to the medications and its components, diabetes mellitus, active peptic ulcers, 
myocardial infarction within the last week, and familial hypokalemic periodic paralysis.25  
 Participants were randomly allocated to either Group 1: propofol, or Group 2: 
dexamethasone, by picking a ballot. The two treatment groups were prognostically balanced in 
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demographics and baseline characteristics. The patients were assessed by a specialist for 
headache severity using a 10-point VAS, as well for symptoms of nausea and vomiting, 
photophobia, and phonophobia before receiving treatment. This specialist was blinded to the 
patient’s assigned group. All patients had an IV line established in their left hand. All injections 
were performed by the same specialist who assessed the patients’ headache severity. The 
injection performer was blinded to the type of injection the patient received by a curtain. All 
patients were blinded to the type of treatment they received as well. Group 1 received a 10mg IV 
infusion of propofol at a rate of 1mL per 10 seconds. An additional 10mg infusion of propofol 
was administered every 5-10 minutes following the initial bolus, up to a maximum dose of 
80mg, until pain was reported as ≤ 2 on the VAS. To reduce possibility of pain at the injection 
site 1mL of 2% lidocaine was added to every 10mL of propofol. The authors of this study 
reported that prior studies showed that this dose would not have effect on headache severity. 
Group 2 received a 4mg/mL IV infusion of dexamethasone dosed at 0.15mg/kg, up to a 
maximum dose of 16mg. The infusion rate was set at 1mL per 10 seconds.25  
 Each patient was reassessed for headache severity at 5, 10, 20, 30, and 45 minutes after 
initiation of their treatment. Pain intensity was significantly lower in the propofol group at all 
times when compared to the dexamethasone group (P= 0.001). As well, the rate of pain intensity 
reduction in the propofol group was faster at all times when compared to the dexamethasone 
group (P= <0.05). See Table III. No significant difference in the two groups’ mean blood 
pressure, heart rate, and O2 saturation was noted. It was observed that 44.4% of the participants 
in the propofol group experienced mild sedation as a complication.25 
 The authors found that the administration protocol for the treatments in this study was a 
limitation. Propofol was administered in titrated doses whereas dexamethasone was administered 
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as a bolus. They were limited to this method due to the lack of a known effective titrated 
protocol for dexamethasone in the treatment of migraine headache. Another mentioned limitation 
in this study was the lack of patient follow-up for assessment of headache recurrence after 
discharge.25  
DISCUSSION 
 Many of the accepted abortive therapies for migraine headaches used in the ED have 
questionable efficacy, leading to poor pain control, unwanted side effects, and possibility of 
readmission to the ED due to headache recurrence.7 Propofol is an anesthetic agent that has been 
proposed as a novel treatment for migraine headache. Many case studies have shown propofol to 
be an effective treatment for reducing migraine headache pain severity and recurrence of 
headache within 24 hours.17,20-23  
 This systematic review investigated two randomized control trials25,26 that compared 
propofols’ effectiveness to other standard abortive therapies including sumatriptan and 
dexamethasone in the treatment of migraine headache. Soleimanpour et al25 revealed that 
propofol overall was more effective at reducing pain severity in migraine headache when 
compared to dexamethasone. Moshtaghion et al26 revealed that propofol was more effective at 
reducing pain severity in migraine headache within 30 minutes after treatment when compared to 
sumatriptan. Both studies showed that the rate at which pain severity was reduced with propofol 
treatment was significantly faster than the other therapies,25,26 results can be seen in Tables II & 
III. These concepts are important when considering length of patient suffering and length of stay 
(LOS) in the ED. A shorter LOS is not only beneficial to the patient but also to overcrowded 
EDs. In one study,27 LOS of pediatric patients with migraine who were treated with propofol was 
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decreased when compared to the control. It is necessary that further studies should include LOS 
in the ED from admission to discharge as one of their assessed outcomes. 
 Moshtaghion et al26 also found propofol to be more effective at reducing nausea, 
vomiting, and headache recurrence within 24 hours when compared to sumatriptan. Again, this is 
important when considering patient suffering but also re-admittance rates to the ED and the costs 
associated. It is important that further studies not only include headache recurrence rates between 
treatment groups but as well as re-admittance rates to the ED for headache and symptom relapse.  
 While the studies25,26 demonstrated that propofol is more effective, they both have 
limitations. The Moshtaghion et al study26 lacked a standard questionnaire when assessing 
patients for headache recurrence. It is possible that individual interviewer styles of inquiring 
about headache recurrence could have affected the patients’ response.  
 The Soleimanpour et al study25 was limited by its medication administration protocol. 
Propofol was administered in titrated doses based on the patients VAS pain reduction score with 
a set maximum dose. Dexamethasone was administered in one bolus dependent on the patient’s 
weight with a set maximum dose as well. It is possible that patients in the dexamethasone group, 
that did not have good response to treatment, still had the ability to receive additional 
dexamethasone without exceeding the maximum dose. It is possible that additional 
administration of dexamethasone, to these patients, could have had an effect in their overall VAS 
pain reduction score.  
 An additional limitation noted between the two studies25,26 was the different dosing 
regimens of propofol. It is possible that treatment response at different time intervals within the 
propofol groups could be dose dependent and prove to have various results when compared to 
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other treatment groups.  In future studies a standardized dosing protocol should be observed in 
the propofol treatment groups to minimize confounding variables.  
CONCLUSION 
 Propofol can be an ideal abortive treatment for acute migraine in the ED. It is rapid 
acting, has few side effects when used at analgesic doses, and may be more effective at reducing 
pain severity, headache recurrence, and accompanying symptoms than sumatriptan and 
dexamethasone. Further studies to assess propofol’s effectiveness as compared to these and other 
standard abortive therapies used in the ED is warranted. These studies should include important 
factors like reduction of accompanying symptoms, adverse effects of the medications, patient’s 
average LOS in the ED, and headache recurrence and rate of re-admission. All of these points are 
important factors when choosing the most effective therapy for migraine headache.  
 .   
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Table I. Grade Evidence Profile, Characteristics of Reviewed Studies 
 
Quality Assessment 
Quality Importance  Downgrade Criteria 
No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Reduction of pain intensity   
2 
 
2 RCT No serious limitations 
No serious 
indirectness Serious
a Seriousb No bias likely Low Critical 
Rate of treatment response   
2 2 RCT No serious limitations 
No serious 
indirectness Serious
a No serious 
inconsistencies No bias likely Moderate Critical 
Recurrence of headache within 24 hours   
1 1 RCT No serious limitations 
No serious 
indirectness 
Very 
Seriousc 
No serious 
inconsistencies No bias likely Low Important 
Unwanted side effects   
1 1 RCT No serious limitations 
No serious 
indirectness 
Very 
Seriousc 
No serious 
inconsistencies No bias likely Low Important 
aOnly two RCTs evaluated this outcome 
bThe  Moshtaghion et al study26 demonstrated increased improvement only at 30 minutes while the Soleimanpour et al study25 demonstrated 
increased improvement at all time frames 
cOnly one RCT evaluated this outcome 
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Summary of Findings 
 
TABLE II. Moshtaghion et al26 
Outcome 
Intervention 
P Valuea Propofol Sumatriptan 
Pain intensity before 
treatment 9.09 +/- 1.02 8.71 +/- 1.20 0.111 
Pain intensity 30 minutes 
after treatment 2.62 +/- 2.12 3.69 +/- 2.55 0.034 
Pain intensity 1 hour after 
treatment 2.69 +/- 2.63 2.36 +/- 2.31 0.53 
Pain intensity 2 hours after 
treatment 1.62 +/- 2.04 1.36 +/- 1.96 0.53 
Recurrence of headache 
within 24 hours 17.1% 55.3% 0.001 
Need for anti-emetic 
therapy 13.3% 33.3% 0.045 
Drowsiness 15.6% 4.4% 0.15 
Chest tightness 2.2% 31.1% 0.001 
Hypotension 2..2% 4.4% 1 
Rash at injection site 0.0% 33.3% 0.001 
aP Values of <0.05 were considered significantly different 
 
 
 
TABLE III. Soleimanpour et al25 
Outcome 
Intervention 
P Valuea Propofol Dexamethasone 
Pain intensity before 
treatment 8 +/- 1.52 8.11 +/- 1.31 0.712 
Pain intensity 5 minutes 
after treatment 5.46 +/- 1.56 6.57 +/- 1.57 0.001 
Pain intensity 10 minutes 
after treatment 3.08 +/- 1.7 5.13 +/- 1.47 <0.001 
Pain intensity 20 minutes 
after treatment 1.87 +/- 1.28 3.73 +/- 1.81 <0.001 
Pain intensity 30 minutes 
after treatment 1.44 +/- 1.63 3.06 +/- 2 <0.001 
Pain intensity 45 minutes 
after treatment 1.16 +/- 1.55 2.87 +/- 1.81 <0.001 
aP Values of <0.05 were considered significantly different 
 
